XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
EXAGEN INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$7.43−0.29 (-3.76%)
Close on Oct 19, 2026
- Market cap
- $179.54M
- P/E (TTM)
- –
- Dividend yield
- –
EXAGEN INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $66.58M | $55.64M | $52.55M | – | – | – | – | – | 100.0% | +19.7% |
| Other | – | – | – | – | – | – | $639.00K | $738.00K | – | – |
| Government | – | – | – | – | – | – | $9.90M | $10.02M | – | – |
| Janssen (SIMPONI) | – | – | – | – | – | – | $1.48M | $0 | – | – |
| Client | – | – | – | – | – | – | $4.39M | $608.00K | – | – |
| Commercial | – | – | – | – | – | – | $23.98M | $21.07M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Exagen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.